Ballentine Partners, LLC Vertex Pharmaceuticals Inc Transaction History

Ballentine Partners, LLC

$5.39 Billion
Q2 2024

A detailed history of Ballentine Partners, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ballentine Partners, LLC holds 5,348 shares of VRTX stock, worth $2.54 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

5,348

Previous 4,878 9.64%

Holding current value

$2.54 Million

Previous $2.04 Million 22.9%

% of portfolio

0.05%

Previous 0.04%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$392.81 - $485.53 $184,620 - $228,199	470 Added 9.64%	5,348 $2.51 Million
Q1 2024 Apr 11, 2024	BUY	$407.69 - $446.08 $125,976 - $137,838	309 Added 6.76%	4,878 $2.04 Million
Q4 2023 Jan 23, 2024	BUY	$343.0 - $410.68 $68,943 - $82,546	201 Added 4.6%	4,569 $1.86 Million
Q3 2023 Oct 19, 2023	BUY	$338.18 - $362.46 $301,656 - $323,314	892 Added 25.66%	4,368 $1.52 Million
Q2 2023 Jul 26, 2023	BUY	$314.42 - $351.91 $41,189 - $46,100	131 Added 3.92%	3,476 $1.22 Million
Q1 2023 Apr 27, 2023	BUY	$283.23 - $323.1 $252,924 - $288,528	893 Added 36.42%	3,345 $1.05 Million
Q4 2022 Jan 27, 2023	BUY	$285.76 - $321.48 $124,591 - $140,165	436 Added 21.63%	2,452 $0
Q3 2022 Oct 26, 2022	BUY	$273.83 - $305.53 $138,010 - $153,987	504 Added 33.33%	2,016 $584,000
Q2 2022 Aug 09, 2022	BUY	$234.96 - $292.55 $30,779 - $38,324	131 Added 9.49%	1,512 $426,000
Q1 2022 May 05, 2022	SELL	$221.42 - $260.97 $61,776 - $72,810	-279 Reduced 16.81%	1,381 $360,000
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $293,836 - $370,927	1,660 New	1,660 $364,000
Q3 2021 Oct 27, 2021	SELL	$181.39 - $202.99 $185,561 - $207,658	-1,023 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$187.49 - $221.1 $15,749 - $18,572	-84 Reduced 7.59%	1,023 $206,000
Q1 2021 May 11, 2021	SELL	$207.02 - $241.31 $26,498 - $30,887	-128 Reduced 10.36%	1,107 $238,000
Q4 2020 Jan 25, 2021	SELL	$207.01 - $276.09 $46,991 - $62,672	-227 Reduced 15.53%	1,235 $291,000
Q3 2020 Oct 22, 2020	BUY	$255.65 - $303.1 $4,090 - $4,849	16 Added 1.11%	1,462 $398,000
Q2 2020 Jul 31, 2020	SELL	$225.48 - $295.8 $11,048 - $14,494	-49 Reduced 3.28%	1,446 $420,000
Q1 2020 Apr 23, 2020	BUY	$199.77 - $247.81 $16,780 - $20,816	84 Added 5.95%	1,495 $356,000
Q4 2019 Jan 22, 2020	BUY	$166.71 - $223.91 $9,669 - $12,986	58 Added 4.29%	1,411 $309,000
Q3 2019 Oct 21, 2019	SELL	$166.23 - $187.09 $1,329 - $1,496	-8 Reduced 0.59%	1,353 $230,000
Q2 2019 Jul 25, 2019	BUY	$164.61 - $190.37 $224,034 - $259,093	1,361 New	1,361 $250,000
Q4 2017 Feb 02, 2018	SELL	$137.28 - $155.55 $250,536 - $283,878	-1,825 Closed	0 $0
Q3 2017 Nov 06, 2017	BUY	$148.13 - $162.24 $270,337 - $296,088	1,825	1,825 $277,000

Others Institutions Holding VRTX

# of Institutions

1,707

Shares Held

226M

Call Options Held

1.2M

Put Options Held

1.59M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ballentine Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ballentine Partners, LLC with notifications on news.

Account

Ballentine Partners, LLC Vertex Pharmaceuticals Inc Transaction History